sotrastaurin: Clinical Trials

20 trials of sotrastaurin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 terminated, 1 withdrawn. 12 Phase 2, 11 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 9, Terminated 2, Withdrawn 1
Phase 111Completed 9, Terminated 2

Follow sotrastaurin: new trials by email Literature Review of sotrastaurin trials Research Report on sotrastaurin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma
Phase 2WithdrawnJames Blachly2015-03-122017-04-05
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
AEB071, BYL719 - Uveal Melanoma
Phase 1CompletedColumbia University302014-11-192023-08-15
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
AEB071, Everolimus - CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Phase 1CompletedNovartis Pharmaceuticals312013-12-052020-12-19
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
AEB071, MEK162 - Uveal Melanoma
Phase 1 / Phase 2TerminatedArray Biopharma, now a wholly owned subsidiary of Pfizer382013-08-012020-09-16
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
AEB071 - Uveal Melanoma
Phase 1CompletedNovartis Pharmaceuticals1532011-12-202020-12-19
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
AEB071 - Diffuse Large B-Cell Lymphoma
Phase 1TerminatedNovartis Pharmaceuticals152011-11-012020-12-19
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
AEB071, Placebo - Ulcerative Colitis
Phase 2CompletedNovartis Pharmaceuticals602010-04-012020-12-22
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients
MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications - Liver Transplantation
Phase 2CompletedNovartis Pharmaceuticals2002010-04-012020-12-22
Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients
sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications - Renal Transplantation
Phase 2CompletedNovartis Pharmaceuticals2982009-12-012020-12-22
CAEB071 Thorough QTc Study in Healthy Volunteers
sotrastaurin, placebo to sotrastaurin, Avelox - Healthy
Phase 1CompletedNovartis Pharmaceuticals1002009-07-012012-05-09
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Placebo, AEB071 - Moderate and Severe Plaque Psoriasis
Phase 2CompletedNovartis Pharmaceuticals3362009-04-012020-12-22
Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients
cyclosporine (reduced exposure) / everolimus, AEB071 300 mg b.i.d. / everolimus, AEB071 200 mg b.i.d. / everolimus - Kidney Transplantation
Phase 2CompletedNovartis Pharmaceuticals1752008-09-012017-02-24
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
AEB071 - Uveitis, Posterior Uveitis
Phase 2CompletedNovartis132008-07-012020-12-22
Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation
AEB071 - de Novo Liver Transplantation
Phase 1CompletedNovartis132007-10-012020-12-08
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
AEB071, mycophenolic plus tacrolimus - Kidney Transplantation
Phase 2TerminatedNovartis Pharmaceuticals1372007-10-012020-12-17
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
AEB071, Certican, Neoral - Kidney Transplantation
Phase 2CompletedNovartis Pharmaceuticals3112007-07-012016-11-18
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
AEB071 - Kidney Transplantation
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals1242007-01-012020-12-22
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
AEB071 - Healthy
Phase 1CompletedNovartis962006-10-012008-08-11
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
AEB071, Mycophenolic Acid - Kidney Transplantation
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals2152006-10-012020-12-17
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
AEB071 - Healthy
Phase 1CompletedNovartis162006-06-012010-10-19

Conditions studied

Rejection, Psychology (3)  ·  Uveal Melanoma (3)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Melanoma (2)  ·  Colitis, Ulcerative (1)  ·  Dermatitis (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Prolymphocytic (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Macular Edema (1)  ·  Neoplasm Metastasis (1)  ·  Panuveitis (1)  ·  Psoriasis (1)  ·  Uveitis (1)

Sponsors

Novartis Pharmaceuticals (13)  ·  Novartis (4)  ·  Array Biopharma, now a wholly owned subsidiary of Pfizer (1)  ·  Columbia University (1)  ·  James Blachly (1)

Countries

United States (14)  ·  Germany (13)  ·  France (9)  ·  Italy (9)  ·  Spain (8)  ·  United Kingdom (8)  ·  Netherlands (7)  ·  Switzerland (7)  ·  Belgium (6)  ·  Canada (6)  ·  Argentina (5)  ·  Australia (4)  ·  Taiwan (4)  ·  Austria (3)  ·  Brazil (3)

Top investigators

James Blachly, MD (1)  ·  Richard Carvajal, MD (1)

Results publications

PMID 21564523, PMID 23659755, PMID 23668931, PMID 25677074

NIH funding

2008 (1), 2009 (1)